Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer
-
- STATUS
- Recruiting
-
- End date
- May 9, 2023
-
- participants needed
- 412
-
- sponsor
- Umeå University
Summary
The study's aim is to define imaging and molecular bio-markers for prediction of radiotherapy response of squamous cell carcinomas, in an early treatment phase.
Description
Patients with squamous cell carcinoma of the head & neck, anal canal, cervix, esophagus or lung will be assessed before start of radiotherapy and 1-2 weeks after start. Multi-parametric MRI and 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) will be performed in parallel to metabolomic analyses of tumour tissue. The investigators will correlate changes in imaging bio-markers to corresponding changes in tissue or blood bio-markers by repeated imaging and biopsies for better understanding of the image parameters.
The data from the two assessments will be used for identifying imaging bio-markers, predictive for outcome. The patient data will be divided into one set of data for hypothesis generation and another set for validation.
Details
| Condition | carcinoma of the cervix uteri, lung carcinoma, oesophageal cancer, Head and Neck Cancer, cancer of the esophagus, squamous cell cancer, epidermoid carcinoma, cervix cancer, Pulmonary Disease, Esophageal Diseases, cancer of the cervix, oesophageal carcinoma, carcinoma of cervix, Carcinoma, Bronchial Neoplasm, Esophageal Cancer, Lung Neoplasm, carcinoma lung, anal carcinoma, Lung Disease, Squamous Cell Carcinoma, head and neck cancer, Rectal Cancer, Squamous cell carcinoma, Anal Cancer, Vulvar Dysplasia and Carcinoma, Uterine Cancer, esophagus cancer, Cervical Cancer, cervical cancer, uterine, Lung Cancer, Esophageal Disorders, cancer of the head and neck, cervical carcinoma, Uterine Serous Carcinoma, Esophageal Carcinoma, Disorders of cervix NOS, Advanced Malignancies, carcinoma of the cervix |
|---|---|
| Clinical Study Identifier | NCT02379039 |
| Sponsor | Umeå University |
| Last Modified on | 9 October 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer